Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer's disease drug candidates

Journal of Molecular Neuroscience

Volumn 47, Issue 1, 2012, Pages 192-203

  Löffler, Tina ^a   Flunkert, Stefanie ^a   Taub, Nicole ^a   Schofield, Emma L ^b   Ward, Malcolm A ^b   Windisch, Manfred ^a   Hutter Paier, Birgit ^a  

^a JSW Life Sciences GmbH   (Austria)

^b Proteome Sciences Plc   (United Kingdom)

Author keywords

Drug development; Hyperphosphorylation; Kinase inhibitor; Tau

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARA 014418; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 5; CYTOKERATIN 1; GLYCOGEN SYNTHASE KINASE 3; IC 261; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RP 106; SERINE; STRESS ACTIVATED PROTEIN KINASE; TAU 441 PROTEIN; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONSTRUCT; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; MUTANT; NEUROBLASTOMA CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SCREENING TEST;

ALZHEIMER DISEASE; ANIMALS; CELL LINE, TUMOR; DRUG DESIGN; GENETIC TESTING; HUMANS; MICE; MICE, TRANSGENIC; MUTAGENESIS; NEUROBLASTOMA; PHARMACOGENETICS; PHOSPHORYLATION; TAU PROTEINS; TAUOPATHIES; TRANSFECTION;

EID: 84859707391     PISSN: 08958696     EISSN: 15591166     Source Type: Journal    
DOI: 10.1007/s12031-012-9716-6     Document Type: Article

References (62)

1. Atzori C, Ghetti B, Piva R et al (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60:1190-1197 (Pubitemid 33117099)
2. Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E (1993) Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett 336:417-424 (Pubitemid 24036992)
3. Bennett BL, Sasaki DT, Murray BW et al (2001) SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686 (Pubitemid 33115958)
4. Blurton-Jones M, Laferla FM (2006) Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 3:437-448 (Pubitemid 46066423)
5. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VM (1993) Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10:1089-1099 (Pubitemid 23194399)
6. Cho JH, Johnson GV (2004) Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3beta (GSK3beta) plays a critical role in regulating tau's ability to bind and stabilize microtubules. J Neurochem 88:349-358
7. Cowan CM, Chee F, Shepherd D, Mudher A (2010) Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans 38:564-570
8. de Calignon A, Fox LM, Pitstick R et al (2010) Caspase activation precedes and leads to tangles. Nature 464:1201-1204
9. Delobel P, Lavenir I, Fraser G et al (2008) Analysis of tau phosphorylation and truncation in a mouse model of human tauopathy. Am J Pathol 172:123-131 (Pubitemid 351186374)
10. Engel T, Hernandez F, Avila J, Lucas JJ (2006) Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 26:5083-5090 (Pubitemid 44315289)
11. Ferrer I, Pastor P, Rey MJ et al (2003) Tau phosphorylation and kinase activation in familial tauopathy linked to deln296 mutation. Neuropathol Appl Neurobiol 29:23-34 (Pubitemid 36238114)
12. Ferrer I, Gomez-Isla T, Puig B et al (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2:3-18 (Pubitemid 41389255)
13. Feuillette S, Miguel L, Frebourg T, Campion D, Lecourtois M (2010) Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J Neurochem 113:895-903
14. Fox LM, William CM, Adamowicz DH et al (2011) Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol 70:588-595
15. Ghoshal N, Smiley JF, DeMaggio AJ et al (1999) A new molecular link between the fibrillar and granulovacuolar lesions of Alzheimer's disease. Am J Pathol 155:1163-1172 (Pubitemid 29488924)
16. Goedert M (1996) Tau protein and the neurofibrillary pathology of Alzheimer's disease. Ann NY Acad Sci 777:121-131
17. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495 (Pubitemid 32807681)
18. Gozes I (2010) Tau pathology and future therapeutics. Curr Alzheimer Res 7:685-696
19. Gozes I (2011) Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des 17:3413-3417
20. Han D, Qureshi HY, Lu Y, Paudel HK (2009) Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J Biol Chem 284:13422-13433
21. Hanger DP, Noble W (2011) Functional implications of glycogen synthase kinase-3-mediated tau phosphorylation. Int J Alzheimers Dis 2011:352805
22. Hanger DP, Byers HL,Wray S et al (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282:23645-23654 (Pubitemid 47311907)
23. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15:112-119
24. Hasegawa M, Crowther RA, Jakes R, Goedert M (1997) Alzheimer-like changes in microtubule-associated protein Tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation. J Biol Chem 272:33118-33124 (Pubitemid 28023655)
25. Hernandez F, Borrell J, Guaza C, Avila J, Lucas JJ (2002) Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem 83:1529-1533 (Pubitemid 35477491)
26. Hoover BR, Reed MN, Su J et al (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067-1081
27. Hutton M, Lendon CL, Rizzu P et al (1998) Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705
28. Johnson GL, Nakamura K (2007) The c-jun kinase/stress-activated pathway: regulation, function and role in human disease. Biochim Biophys Acta 1773:1341-1348 (Pubitemid 47125977)
29. Kuret J, Johnson GS, Cha D, Christenson ER, DeMaggio AJ, Hoekstra MF (1997) Casein kinase 1 is tightly associated with pairedhelical filaments isolated from Alzheimer's disease brain. J Neurochem 69:2506-2515 (Pubitemid 27495438)
30. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4:222
31. Li G, Yin H, Kuret J (2004) Casein kinase 1 delta phosphorylates tau and disrupts its binding to microtubules. J Biol Chem 279:15938-15945 (Pubitemid 38509281)
32. Liao X, Zhang Y, Wang Y, Wang J (2004) The effect of cdk-5 over-expression on tau phosphorylation and spatial memory of rat. Sci China C Life Sci 47:251-257
33. Liu T, Perry G, Chan HW, Verdile G, Martins RN, Smith MA, Atwood CS (2004) Amyloid-beta-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression. J Neurochem 88:554-563 (Pubitemid 38140200)
34. Lopez MF, Kuppusamy R, Sarracino DA et al (2011) Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum. J Proteome Res 10:133-142
35. Mashhoon N, DeMaggio AJ, Tereshko V et al (2000) Crystal structure of a conformation-selective casein kinase-1 inhibitor. J Biol Chem 275:20052-20060 (Pubitemid 30441614)
36. Matsuoka Y, Gray AJ, Hirata-Fukae C et al (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31:165-170 (Pubitemid 46742300)
37. Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 6:464-479 (Pubitemid 47064569)
38. Medina M, Avila J (2010) Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease. Curr Pharm Des 16:2790-2798
39. Medina M, Castro A (2008) Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. CurrOpin Drug Discov Devel 11:533-543 (Pubitemid 351950847)
40. Mettey Y, Gompel M, Thomas V et al (2003) Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem 46:222-236 (Pubitemid 36078142)
41. Moreno H, Choi S, Yu E et al (2011) Blocking effects of human tau on squid giant synapse transmission and its prevention by T-817 MA. Front Synaptic Neurosci 3:3
42. Mudher A, Shepherd D, Newman TA et al (2004) GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry 9:522-530 (Pubitemid 38903508)
43. Nacharaju P, Lewis J, Easson C, Yen S, Hackett J, Hutton M, Yen SH (1999) Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett 447:195-199 (Pubitemid 29146084)
44. Noble W, Olm V, Takata K et al (2003) Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:555-565 (Pubitemid 36645031)
45. Otth C, Concha II, Arendt T et al (2002) AbetaPP induces cdk5-dependent tau hyperphosphorylation in transgenic mice Tg2576. J Alzheimers Dis 4:417-430 (Pubitemid 35397807)
46. Patrick GN, Zukerberg L, Nikolic M, de la MS, Dikkes P, Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402:615-622 (Pubitemid 129516324)
47. Pei JJ, Braak E, Braak H et al (1999) Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol 58: 1010-1019 (Pubitemid 29441929)
48. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH (2000) Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 74:1587-1595 (Pubitemid 30163980)
49. Sang H, Lu Z, Li Y, Ru B, Wang W, Chen J (2001) Phosphorylation of tau by glycogen synthase kinase 3beta in intact mammalian cells influences the stability of microtubules. Neurosci Lett 312:141-144 (Pubitemid 32972143)
50. Santa Cruz K, Lewis J, Spires T et al (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:476-481 (Pubitemid 40994688)
51. Schofield EL, Duller S, Pike I, Hutter-Paier B (2011) Phospho-TAU SRM - a multi-site phosphorylation assay for assessing mouse models and drug development in Alzheimer's disease. AAICAD [Poster P2-066], S325. 2011
52. Shiryaev N, Pikman R, Giladi E, Gozes I (2011) Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects. Curr Pharm Des 17:2603-2612
53. Singh TJ, Haque N, Grundke-Iqbal I, Iqbal K (1995) Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett 358:267-272
54. Takashima A, Honda T, Yasutake K et al (1998) Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci Res 31:317-323 (Pubitemid 28446014)
55. Tatebayashi Y, Planel E, Chui DH et al (2006) c-jun N-terminal kinase hyperphosphorylates R406W tau at the PHF-1 site during mitosis. FASEB J 20:762-764 (Pubitemid 46671207)
56. Town T, Zolton J, Shaffner R et al (2002) p35/Cdk5 pathway mediates soluble amyloid-beta peptide-induced tau phosphorylation in vitro. J Neurosci Res 69:362-372 (Pubitemid 34809485)
57. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E (1995) Domains of tau protein, differential phosphorylation, and dynamic instability of microtubules. Mol Biol Cell 6:1887-1902
58. Wagner U, Utton M, Gallo JM, Miller CC (1996) Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 109(Pt 6):1537-1543
59. Wang JZ, Liu F (2008) Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog Neurobiol 85:148-175
60. Wray S, Saxton M, Anderton BH, Hanger DP (2008) Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats. J Neurochem 105:2343-2352 (Pubitemid 351782262)
61. Yanagi K, Tanaka T, Kato K, Sadik G, Morihara T, Kudo T, Takeda M (2009) Involvement of puromycin-sensitive aminopeptidase in proteolysis of tau protein in cultured cells, and attenuated proteolysis of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) mutant tau. Psychogeriatrics 9:157-166
62. Yasojima K, Kuret J, DeMaggio AJ, McGeer E, McGeer PL (2000) Casein kinase 1 delta mRNA is upregulated in Alzheimer disease brain. Brain Res 865:116-120 (Pubitemid 30256215)